Table 1

Characteristics of patients with SpA not treated or treated with TNF inhibitors

SpA (n=11)SpA+anti-TNF (n=20*)
Disease duration (years)4 (0.7–20)9 (00.8–20)
Age (years)29.5 (22–38)30 (22–40)
BASDAI4.38 (2.7–7.1)1.5 (0–3.78)
CRP (mg/l)7.5 (3–176)5.0 (3–67)
Treatment
Infliximab, n016
Etanercept, n03
Adalimumab, n01
Sulfasalazine, n20
Methotrexate, n15
Azathioprine, n01
NSAID, n40
Duration of anti-TNF treatment before sperm analysis (months)27 (4–57)
  • * Fifteen long-term plus five de novo anti-TNF treated patients;

  • median (range).

  • BASDAI, Bath Ankylosing Spondylitis Disease Activity Index, CRP, C-reactive protein; NSAID, non-steroidal anti-inflammatory drugs; SpA, spondyloarthritis; TNF, tumour necrosis factor.